Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24863783 | 0.84 | AR (0.64) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL24863637 | 0.84 | AR (0.68) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL26799878 | 0.81 | AR (0.74) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL1259286 | 0.80 | AR (0.63) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL10248206 | 0.80 | AR (0.58) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL5987289 | 0.80 | AR (0.62) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL5530181 | 0.80 | AR (0.63) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL2148549 | 0.80 | AR (0.63) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL5519427 | 0.80 | AR (0.63) | ARGAAHTTKDM4EPOLB | |
| SCHEMBL1637458 | 0.79 | AR (0.68) | ARGAAHTTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20100324095-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-12-23 | — | — | US | disclosed |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2010-11-25 | — | — | US | disclosed |
| US-7795446-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7566733-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-28 | — | — | US | disclosed |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | NG RAYMOND | 2008-05-22 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
| EP-1812406-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1805147-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006039215-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006039243-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | AR 1/4885GAA 2241/4885HTT 4287/4885 |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | AR 1/4885GAA 2241/4885HTT 4287/4885 |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885GAA 3192/4885HTT 3639/4885 |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885GAA 3192/4885HTT 3639/4885 |
| US-20100324095-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, APBA1 | AR 3720/4885GAA 173/4885HTT 31/4885 |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | AR, NR5A1, ESRRA | AR 1/4885GAA 2241/4885HTT 4287/4885 |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | AR, FSHR, BRDT | AR 1/4885GAA 1683/4885HTT 1609/4885 |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | AR, NR5A1, ESRRA | AR 1/4885GAA 2241/4885HTT 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.